Second-generation H1 antihistamines fail to control symptoms in a substantial share of patients with chronic inducible urticaria (CIndU), and Dermatology Times' latest clinical review examines why the standard therapy falls short.

The review, published by Dermatology Times, centers on the gap between guideline-recommended dosing and real-world response in CIndU, a form of chronic urticaria triggered by specific physical stimuli rather than spontaneous whealing.

What's driving the treatment gap?

CIndU subtypes — including cold urticaria, symptomatic dermographism, cholinergic urticaria and delayed-pressure urticaria — have distinct trigger pathways, and the review argues that a one-size-fits-all antihistamine approach leaves many patients under-treated.

The headline finding for clinicians: relying on labeled doses of second-generation H1 agents leaves a meaningful proportion of CIndU patients symptomatic, pushing dermatologists toward up-dosing and add-on strategies.

Why the standard approach isn't enough

Second-generation H1 antihistamines remain first-line therapy, but their histamine-receptor blockade doesn't address the full mast-cell-driven pathway behind inducible urticaria. That mechanistic mismatch, the review explains, underlies the frequent need for dose escalation beyond licensed labeling.

For patients who don't respond after up-dosing, current practice moves to second-line agents — with omalizumab, the anti-IgE biologic, the established next step in refractory disease.

What should dermatologists take from this?

The piece serves as a practical reminder for clinicians: assess CIndU subtype, document response at each dose step, and don't leave patients parked on ineffective first-line dosing.

The review signals a broader shift in urticaria management — from antihistamine-centric care toward mechanism-matched therapy for the subset of CIndU patients the standard pathway doesn't reach.

Note: This summary is based on the Dermatology Times article headline and framing; readers should consult the full article for the specific trial data and dosing details.